Eli Lilly expects Medicare about-face on Alzheimer’s drugs coverage
By
Alicia Lasek
Apr 23, 2023
New data on Lilly’s experimental drug donanemab may influence CMS’s restrictive stance on coverage of this and other amyloid-busting Alzheimer’s treatments, a company executive says.
Senior care scores some wins in congressional budget deal
By
Alicia Lasek
Dec 21, 2022
A Congressional spending package for fiscal year 2023 supports key healthcare policy requests important to long-term care industry stakeholders, saving some clinicians and services from feared cuts.
Aduhelm’s costs: Medicare recipients won’t get premium reduction until 2023
By
Alicia Lasek (f3)
Jun 01, 2022
A cost overestimate that bumped up Medicare premiums for seniors in 2022 will not be corrected until the following year. The spike is tied to coverage for Alzheimer’s drug Aduhelm.